Alzheimer’s Disease Therapeutics & Diagnostics Market By Therapeutics (Biomarkers, Cholinesterase Inhibitors, NMDA Receptor Antagonists), Diagnostics (Brain Imaging, Blood Tests), By Imaging Technologies (Structural Imaging, Molecular Imaging) , Industry Size, Growth, Share And Forecast To 2022
Key Findings
The global alzheimer’s disease therapeutics and diagnostics market is expected to grow at the CAGR of 7.1% during 2015-2022, and it expected to reach $7200 million till 2022.Alzheimer disease is caused due to abnormal working of brain cells, resulting in loss of cognitive functions due to failure of synaptic transmission. There are various symptoms of alzheimer disease like repetitive movement, agitation, insomnia, memory loss, depression, loss of reasoning abilities and so on. Alzheimer’s disease may even leads to death at its severe stage. Alzheimer’s disease is the common form of dementia, According to National Institute of Aging.
The growth of global alzheimer’s disease therapeutics and diagnostics market is based on various factors. The major factor driving the market is high prevalence rate of alzheimer’s disease. Alzheimer diseases is mainly found in elders, 1 out of 3 senior citizens dies due to alzheimer diseases. This leads to increase in the treatment and diagnostic expenditure againstalzheimer’s disease that enhance the global market.
Investment on biomarkers for drug development is one of the major reason for the growth of global alzheimer market. Biomarker is a naturally occurring gene, molecule by which a particular pathological process can be identified. Alzheimer is one of the chronic disease that took millions of lives across the globe. Investment on R&D for manufacturing result oriented drug to heal Alzheimer’s is also very high and it is boosting the global market.
Strict regulations, consumption of long timefor approval ofAlzheimer’s disease therapeutics and expiry of several patent drugs are some of the major factors restraining the growth for the global alzheimer’s disease market.
Market Segment Insight
Theglobal alzheimer’s disease therapeutics and diagnostics market is majorly segmented intotherapeutics, diagnostics, imaging technologies and regional outlook.On the basis of therapeutics, the market is divided into biomarkers, cholinesterase inhibitors, and NMDA receptor antagonists.Blood biomarkers help to detect the early onset of alzheimer’s which would help in the treatment of the disease. Investment in the production of biomarkers is considered to be an advantage for the companies, as it is a profitable market. There is a lack of surrogate markers for drug discovery and development. Development of surrogate markers will have definite effectiveness for the treatment of neurologic or psychiatric disease.On the basis of diagnostics segment, the market is divided into brain imaging and blood tests. Brain imaging and blood tests, both plays an important role in identifying the alzheimer disease.
On the basis of imaging technologies, the market is divided into structural imaging, functional imaging and molecular imaging. Market of structural imaging is high as compare to the other two.Regionally the market is divided into North America, Europe, Asia Pacific and Rest of the World. Asia Pacific is the fastest growing region in alzheimer’s disease therapeutics and diagnostics market owing to increase in R&D investment, large population etc. High population of the adults in the country like India and China is another reason for the growth of the market.
Asia Pacific is being followed by Europe in the terms of growth owing to improvement in the healthcare infrastructure and rising geriatric population etc. are the major factor pushing the European region upward. North America is leader in the global alzheimer’s disease therapeutics and diagnostics market due to large number of aging population, technological advancement in the field of pharmaceutical, high prevalence of alzheimer disease etc. Apart from this, Rest of the world is a market showing a very slower rate of market growth.
Regional Insight
The global alzheimer’s disease therapeutics and diagnostics market is divided into North America, Europe, Asia Pacific and Rest of the World.North America is leader in the global alzheimer’s disease therapeutics and diagnostics market owing to large number of aging population, technological advancement in the field of pharmaceutical, high prevalence of alzheimer disease etc. Asia Pacific is the fastest growing region in alzheimer’s disease therapeutics and diagnostics market in the forecasted year. Major reason for the growth are again large population, increasing R&D investment etc. Europe is being followed by Asia Pacific due to improvement of healthcare infrastructure and rising geriatric population and these are the major factor driving the Europe a step forward. Rest of the world is witnessing slow growth, however increasing awareness regarding alzheimer disease in this region is expected to grow the market to some extent.
Competitive Insight
Some of the keymarket players are Daiichi Sankyo Co, Axon Neuroscience,Navidea Biopharmaceuticals, Merck & Co, Janssen Pharmaceuticals, GE healthcare, F. Hoffmann La Roche AG, Eli Lilly, etc. Acquisitions, new product development, collaborations, joint ventures, mergers and expansions are the key strategies adopted by the market players to sustain in the market. In November 2015 GE healthcare acquired Camden Group.
CHAP 1. METHODOLOGY & SCOPE 13
1.1. RESEARCH METHODOLOGY 13
1.2. RESEARCH SCOPE & ASSUMPTIONS 13
1.3. LIST OF DATA SOURCES 13
CHAP 2. EXECUTIVE SUMMARY 14
2.1. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET SUMMARY & KEY BUYING CRITERIA 14
2.2. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK 14
2.3. MARKET SEGMENTATION ANALYSIS 14
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 14
2.5. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET VALUE CHAIN ANALYSIS 14
2.6. VENDOR LANDSCAPE 14
CHAP 3. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 15
3.1. MARKET DRIVER ANALYSIS 15
3.1.1. INCREASING PREVALENCE OF ALZHEIMERS DISEASE 15
3.1.2. INCREASING PIPELINE DRUG DEVELOPMENT 15
3.1.3. INVESTMENT ON BIOMARKERS FOR DRUG DEVELOPMENT 15
3.2. MARKET RESTRAINT ANALYSIS 15
3.2.1. EARLY DIAGNOSIS OF THE INDICATION IS CHALLENGING 15
3.2.2. LACK OF SURROGATE MARKET FOR DRUG DISCOVERY AND DRUG DEVELOPMENT 15
3.3. KEY OPPORTUNITIES 15
3.3.1. STRONG R&D IN NEURODEGENERATIVE DISEASES 15
3.3.2. ADVANCEMENT IN DIAGNOSTIC TECHNOLOGIES WILL IMPROVE DRUG MARKET PENETRATION 15
3.4. CHALLENGES 15
3.4.1. NEW ALZHEIMERS DISEASE THERAPIES FACE POLITICAL, COMMERCIAL AND SOCIAL PRESSURE 15
CHAP 4. INDUSTRY ANALYSIS 16
4.1. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET– PORTER’S FIVE FORCE MODEL 16
4.2. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET– PESTEL ANALYSIS 16
4.3. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET– GAP ANALYSIS 16
CHAP 5. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS 2012-2022 ($ MILLION) 17
5.1. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY BIOMARKERS 2012-2022 ($ MILLION) 17
5.2. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY CHOLINESTERASE INHIBITORS 2012-2022 ($ MILLION) 17
5.3. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY NMDA RECEPTOR ANTAGONISTS 2012-2022 ($ MILLION) 17
CHAP 6. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY DIAGNOSTICS 2012-2022 ($ MILLION) 18
6.1. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY BRAIN IMAGING 2012-2022 ($ MILLION) 18
6.2. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY BLOOD TESTS 2012-2022 ($ MILLION) 18
CHAP 7. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY IMAGING TECHNOLOGIES 2012-2022 ($ MILLION) 19
7.1. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY STRUCTURAL IMAGING 2012-2022 ($ MILLION) 19
7.2. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY FUNCTIONAL IMAGING 2012-2022 ($ MILLION) 19
7.3. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY MOLECULAR IMAGING 2012-2022 ($ MILLION) 19
CHAP 8. GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 20
8.1. GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY REGION 2012-2022 ($ MILLION) 20
8.2. NORTH AMERICA 20
8.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
8.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 20
8.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
8.2.3.1. U.S. 20
8.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
8.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
8.2.3.2. CANADA 20
8.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
8.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
8.2.3.3. MEXICO 20
8.2.3.3.1. MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
8.2.3.3.2. MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
8.3. EUROPE 21
8.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
8.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 21
8.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
8.3.3.1. GERMANY 21
8.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
8.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
8.3.3.2. UK 21
8.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
8.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
8.3.3.3. FRANCE 21
8.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
8.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
8.3.3.4. SPAIN 21
8.3.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
8.3.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
8.3.3.5. REST OF EUROPE 21
8.3.3.5.1. REST OF EUROPE MARKET ESTIMATES AND FORECAST2012-2022($MILLION) 22
8.3.3.5.2. REST OF EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($MILLION) 22
8.4. ASIA PACIFIC 22
8.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
8.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 22
8.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
8.4.3.1. CHINA 22
8.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
8.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
8.4.3.2. INDIA 22
8.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
8.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
8.4.3.3. JAPAN 22
8.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
8.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($MILLION) 22
8.4.3.4. AUSTRALIA 22
8.4.3.4.1. AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
8.4.3.4.2. AUSTRALIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($MILLION) 22
8.4.3.5. REST OF APAC 23
8.4.3.5.1. REST OF APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 23
8.4.3.5.2. REST OF APAC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 23
8.5. REST OF THE WORLD 23
8.5.1. REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 23
8.5.2. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 23
8.5.3. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 23
8.5.3.1. LATIN AMERICA 23
8.5.3.1.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 23
8.5.3.1.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 23
8.5.3.2. MIDDLE EAST AND AFRICA 23
8.5.3.2.1. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 23
8.5.3.2.2. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 23
CHAP 9. COMPETITIVE LANDSCAPE 24
9.1. ABBVIE INC. 25
9.1.2. SCOT ANALYSIS 25
9.1.3. PRODUCT BENCHMARKING 25
9.1.4. STRATEGIC INITIATIVES 25
9.2. AC IMMUNE SA 25
9.2.2. SCOT ANALYSIS 25
9.2.3. PRODUCT BENCHMARKING 25
9.2.4. STRATEGIC INITIATIVES 25
9.3. ALLERGAN PLC 25
9.3.2. SCOT ANALYSIS 25
9.3.3. PRODUCT BENCHMARKING 25
9.3.4. STRATEGIC INITIATIVES 25
9.4. AMARANTUS BIOSCIENCE HOLDINGS 25
9.4.2. PRODUCT BENCHMARKING 25
9.4.3. STRATEGIC INITIATIVES 25
9.5. ANAVEX LIFE SCIENCES 25
9.5.2. SCOT ANALYSIS 25
9.5.3. PRODUCT BENCHMARKING 25
9.5.4. STRATEGIC INITIATIVES 25
9.6. AVID RADIOPHARMACEUTICALS 25
9.6.2. SCOT ANALYSIS 25
9.6.3. PRODUCT BENCHMARKING 26
9.6.4. STRATEGIC INITIATIVES 26
9.7. AXON NEUROSCIENCE 26
9.7.2. SCOT ANALYSIS 26
9.7.3. PRODUCT BENCHMARKING 26
9.7.4. STRATEGIC INITIATIVES 26
9.8. AXOVANT SCIENCES 26
9.8.2. SCOT ANALYSIS 26
9.8.3. PRODUCT BENCHMARKING 26
9.8.4. STRATEGIC INITIATIVES 26
9.9. DAIICHI SANKYO CO 26
9.9.2. SCOT ANALYSIS 26
9.9.3. PRODUCT BENCHMARKING 26
9.9.4. STRATEGIC INITIATIVES 26
9.10. ELI LILLY 26
9.10.2. SCOT ANALYSIS 26
9.10.3. PRODUCT BENCHMARKING 26
9.10.4. STRATEGIC INITIATIVES 26
9.11. F. HOFFMANN LA ROCHE AG 26
9.11.2. SCOT ANALYSIS 26
9.11.3. PRODUCT BENCHMARKING 26
9.11.4. STRATEGIC INITIATIVES 26
9.12. GE HEALTHCARE 27
9.12.2. SCOT ANALYSIS 27
9.12.3. PRODUCT BENCHMARKING 27
9.12.4. STRATEGIC INITIATIVES 27
9.13. JANSSEN PHARMACEUTICALS 27
9.13.2. SCOT ANALYSIS 27
9.13.3. PRODUCT BENCHMARKING 27
9.13.4. STRATEGIC INITIATIVES 27
9.14. MERCK & CO 27
9.14.2. SCOT ANALYSIS 27
9.14.3. PRODUCT BENCHMARKING 27
9.14.4. STRATEGIC INITIATIVES 27
9.15. NAVIDEA BIOPHARMACEUTICALS 27
9.15.2. SCOT ANALYSIS 27
9.15.3. PRODUCT BENCHMARKING 27
9.15.4. STRATEGIC INITIATIVES 27
TABLE 1 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS 2012-2022 ($ MILLION) 27
TABLE 2 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY BIOMARKERS 2012-2022 ($ MILLION) 27
TABLE 3 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY CHOLINESTERASE INHIBITORS 2012-2022 ($ MILLION) 27
TABLE 4 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY NMDA RECEPTOR ANTAGONISTS 2012-2022 ($ MILLION) 28
TABLE 5 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY DIAGNOSTICS 2012-2022 ($ MILLION) 28
TABLE 6 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY BRAIN IMAGING 2012-2022 ($ MILLION) 28
TABLE 7 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY BLOOD TESTS 2012-2022 ($ MILLION) 28
TABLE 8 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY IMAGING TECHNOLOGIES 2012-2022 ($ MILLION) 28
TABLE 9 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY STRUCTURAL IMAGING 2012-2022 ($ MILLION) 28
TABLE 10 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY FUNCTIONAL IMAGING 2012-2022 ($ MILLION) 28
TABLE 11 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY MOLECULAR IMAGING 2012-2022 ($ MILLION) 28
TABLE 12 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 28
TABLE 13 GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY REGION 2012-2022 ($ MILLION) 28
TABLE 14 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 15 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 28
TABLE 16 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 17 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 18 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 19 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 28
TABLE 20 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 28
TABLE 21 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 22 MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 23 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 24 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 29
TABLE 25 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 26 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 27 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 28 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 29 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 30 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 31 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 32 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 33 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 29
TABLE 34 REST OF EUROPE MARKET ESTIMATES AND FORECAST2012-2022($ MILLION) 29
TABLE 35 REST OF EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ MILLION) 29
TABLE 36 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 29
TABLE 37 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 29
TABLE 38 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 39 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 40 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 41 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 42 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 43 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 44 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 45 AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 46 AUSTRALIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 47 REST OF APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 48 REST OF APAC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 49 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 50 REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 30
TABLE 51 REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 52 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 53 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 30
TABLE 54 MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 30
TABLE 55 MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 31
FIGURE 1 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 2 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 4 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 5 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 6 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 7 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 8 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 9 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 10 REST OF EUROPE MARKET ESTIMATES AND FORECAST2012-2022($ MILLION) 31
FIGURE 11 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 12 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 13 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 31
FIGURE 14 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 15 AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 16 REST OF APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 17 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 18 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 19 MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)